• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Big Cypress Acquisition Corp.

    10/19/21 9:51:57 AM ET
    $BCYP
    Finance
    Get the next $BCYP alert in real time by email
    SC 13G 1 tm2130492d1_sc13g.htm BIG CYPRESS ACQUISITION CORP.

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No.    )

     

    Big Cypress Acquisition Corp.
    (Name of Issuer)
     
    Common stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    089115109
    (CUSIP Number)
     
    October 13, 2021
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    oRule 13d-1(b)
    xRule 13d-1(c)
    oRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Radcliffe Capital Management, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,296,891

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    1,296,891

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,296,891

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.77%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

           

     

     

     

     

    1.

    NAME OF REPORTING PERSONS

     

    RGC Management Company, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,296,891

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    1,296,891

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,296,891

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.77%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, OO

           

     

     

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Steven B. Katznelson

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

    3.

    SEC USE ONLY

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Canada, United States of America and the United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,296,891

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    1,296,891

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,296,891

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.77%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Christopher Hinkel

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

    3.

    SEC USE ONLY

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,296,891

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    1,296,891

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,296,891

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.77%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Radcliffe SPAC Master Fund, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,296,891

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    1,296,891

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,296,891

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.77%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

           

     

     

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Radcliffe SPAC GP, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,296,891

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    1,296,891

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,296,891

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.77%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, OO

           

     

     

     

     

    Item 1(a).

    Name of Issuer:

    Big Cypress Acquisition Corp.

       
    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    300 W. 41st St., Suite 202

    Miami Beach, FL 33140

       
    Item 2(a). Name of Person Filing:
     

    Radcliffe Capital Management, L.P.

    RGC Management Company, LLC

    Steven B. Katznelson

    Christopher Hinkel

    Radcliffe SPAC Master Fund, L.P.

    Radcliffe SPAC GP, LLC

       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
     

    50 Monument Road, Suite 300

    Bala Cynwyd, PA 19004

       
    Item 2(c). Citizenship:
     

    Radcliffe Capital Management, L.P. – Delaware, United States of America

    RGC Management Company, LLC – Delaware, United States of America

    Steven B. Katznelson – Canada, United States of America and the United Kingdom

    Christopher Hinkel – United States of America

    Radcliffe SPAC Master Fund, L.P. – Cayman Islands

    Radcliffe SPAC GP, LLC – Delaware, United States of America

       
    Item 2(d). Title of Class of Securities:
      Common stock, par value $0.0001 per share
       
    Item 2(e). CUSIP Number:
     

    089115109

       
    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) o An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

      (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

    Item 4. Ownership:
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)

    Amount beneficially owned:

     

    1,296,891 shares deemed beneficially owned by Radcliffe Capital Management, L.P.

    1,296,891 shares deemed beneficially owned by RGC Management Company, LLC

    1,296,891 shares deemed beneficially owned by Steven B. Katznelson

    1,296,891 shares deemed beneficially owned by Christopher Hinkel

    1,296,891 shares deemed beneficially owned by Radcliffe SPAC Master Fund, L.P.

    1,296,891 shares deemed beneficially owned by Radcliffe SPAC GP, LLC

         
      (b)

    Percent of class:

     

    8.77% shares deemed beneficially owned by Radcliffe Capital Management, L.P.

    8.77% shares deemed beneficially owned by RGC Management Company, LLC

    8.77% shares deemed beneficially owned by Steven B. Katznelson

    8.77% shares deemed beneficially owned by Christopher Hinkel

    8.77% shares deemed beneficially owned by Radcliffe SPAC Master Fund, L.P.

    8.77% shares deemed beneficially owned by Radcliffe SPAC GP, LLC

         
      (c) Number of shares as to which Radcliffe Capital Management, L.P. has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 1,296,891
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 1,296,891
           
        Number of shares as to which RGC Management Company, LLC has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 1,296,891
        (iii) Sole power to dispose or to direct the disposition of: 0

     

     

     

     

        (iv) Shared power to dispose or to direct the disposition of: 1,296,891
           
        Number of shares as to which Steven B. Katznelson has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 1,296,891
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 1,296,891
           
        Number of shares as to which Christopher Hinkel has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 1,296,891
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 1,296,891
           
        Number of shares as to which Radcliffe SPAC Master Fund, L.P. has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 1,296,891
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 1,296,891
           
        Number of shares as to which Radcliffe SPAC GP, LLC has:
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 1,296,891
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 1,296,891
           
    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o Not applicable
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      With the exception of the securities reported in this Schedule 13G that are owned by the Radcliffe SPAC Master Fund, L.P., none of Radcliffe Capital Management, L.P.’s advisory clients individually own more than 5% of the Issuer’s outstanding common stock.

     

     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      See Exhibit B attached hereto.
       
    Item 8. Identification and Classification of Members of the Group:
      Not applicable
       
    Item 9. Notice of Dissolution of Group:
      Not applicable
       
    Item 10. Certifications:
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      October 19, 2021
      (Date)
       

     

     

    Radcliffe Capital Management, L.P.

    By RGC Management Company, LLC,

    its General Partner*

     

    /s/ Loretta Best
    Signature
    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

         
         
    RGC Management Company, LLC*   /s/ Loretta Best
    Signature
    Attorney-in Fact for Steven B. Katznelson
    Managing Member**
         
         
    Steven B. Katznelson*  

    /s/ Loretta Best
    Signature
    Attorney-in Fact**

         
         
    Christopher Hinkel*  

    /s/ Loretta Best
    Signature
    Attorney-in Fact** 

         
         

    Radcliffe SPAC Master Fund, L.P.

    By Radcliffe SPAC GP, LLC,

    its General Partner*

     

    /s/ Loretta Best
    Signature
    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

         
         
    Radcliffe SPAC GP, LLC*  

    /s/ Loretta Best
    Signature
    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

     

    *The Reporting Person specifically disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

     

    **Loretta Best is signing on behalf of Steven B. Katznelson and Christopher Hinkel as attorney-in-fact pursuant to powers of attorney filed with the Securities and Exchange Commission as Exhibits 99.1 and 99.2, respectively, to a filing by Radcliffe Capital Management, L.P. on Schedule 13G on August 30, 2021.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (see 18 U.S.C. 1001).

     

     

     

     

    Exhibit A

     

    Agreement

     

    The undersigned agree that this Schedule 13G dated October 19, 2021 to the Common stock, par value $0.0001 per share of Big Cypress Acquisition Corp. shall be filed on behalf of the undersigned. 

     

      October 19, 2021
      (Date)
       

     

     

    Radcliffe Capital Management, L.P.

    By RGC Management Company, LLC,

    Its General Partner

     

    /s/ Loretta Best
    Signature
    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

         
         
    RGC Management Company, LLC   /s/ Loretta Best
    Signature
    Attorney-in Fact for Steven B. Katznelson
    Managing Member**
         
         
    Steven B. Katznelson  

    /s/ Loretta Best
    Signature
    Attorney-in Fact**

         
         
    Christopher Hinkel  

    /s/ Loretta Best
    Signature
    Attorney-in Fact**

         
         

    Radcliffe SPAC Master Fund, L.P.

    By Radcliffe SPAC GP, LLC,

    its General Partner

     

    /s/ Loretta Best
    Signature

    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

         
         
    Radcliffe SPAC GP, LLC  

    /s/ Loretta Best
    Signature
    Attorney-in Fact for Steven B. Katznelson
    Managing Member**

     

    **Loretta Best is signing on behalf of Steven B. Katznelson and Christopher Hinkel as attorney-in-fact pursuant to powers of attorney filed with the Securities and Exchange Commission as Exhibits 99.1 and 99.2, respectively, to a filing by Radcliffe Capital Management, L.P. on Schedule 13G on August 30, 2021.

     

     

     

     

    Exhibit B

     

    Radcliffe Capital Management, L.P. is the relevant entity for which RGC Management Company, LLC, Steven B. Katznelson and Christopher Hinkel may be considered control persons. Radcliffe SPAC Master Fund, L.P. is the relevant entity for which Radcliffe SPAC GP, LLC, Steven B. Katznelson and Christopher Hinkel may be considered control persons.

     

     

     

     

    Get the next $BCYP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCYP

    DatePrice TargetRatingAnalyst
    10/4/2021$18.00Outperform
    Northland Capital Markets
    10/1/2021$16.50Buy
    Ladenburg Thalmann
    More analyst ratings

    $BCYP
    Leadership Updates

    Live Leadership Updates

    See more
    • SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

      SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB's financial operations and key supporting functions and will work with the senior management team to drive SAB's growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005435/en/(Photo: Business Wire) "We welcome Russell to the SAB team at an exciting t

      9/28/21 7:00:00 AM ET
      $BCYP
      Finance

    $BCYP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

      Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol "SABS" SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of its business combination with Big Cypress Acquisition Corp. (NASDAQ:BCYP) ("Big Cypress"), a publicly-traded special purpose acquisition company (SPAC) focused on innovative biopharmaceutical

      10/25/21 7:39:57 AM ET
      $BCYP
      Finance
    • Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

      MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease and immune system disorders, at a Special Meeting of stockholders held on October 20, 2021 (the "Special Meeting"). Approximately 98.3% of t

      10/21/21 7:00:00 AM ET
      $BCYP
      Finance
    • SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

      SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m. ET to showcase its versatile DiversitAb™ platform and pipeline of clinical and preclinical programs. The event will feature SAB management and key opinion leaders, including: Arturo Casadevall, MD, PhD – The Alfred and Jill Sommer Professor and Chair, W. Harry Feinstone Department of Molecular Microbiology & Immunology, Bloomberg Distinguished Professor, Johns Hopkins B

      10/6/21 7:00:00 AM ET
      $BCYP
      Finance

    $BCYP
    SEC Filings

    See more
    • Big Cypress Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status

      8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

      10/28/21 5:16:44 PM ET
      $BCYP
      Finance
    • SEC Form 25-NSE filed by Big Cypress Acquisition Corp.

      25-NSE - Big Cypress Acquisition Corp. (0001833214) (Subject)

      10/22/21 4:18:33 PM ET
      $BCYP
      Finance
    • Big Cypress Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Big Cypress Acquisition Corp. (0001833214) (Filer)

      10/21/21 7:30:47 AM ET
      $BCYP
      Finance

    $BCYP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Carillo Carlos N

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:53:55 PM ET
      $BCYP
      Finance
    • SEC Form 4 filed by Erickson Bruce Kipp

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:53:05 PM ET
      $BCYP
      Finance
    • SEC Form 4 filed by Wu Hua

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:52:27 PM ET
      $BCYP
      Finance

    $BCYP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Northland Capital Markets initiated coverage on Big Cypress Acquisition with a new price target

      Northland Capital Markets initiated coverage of Big Cypress Acquisition with a rating of Outperform and set a new price target of $18.00

      10/4/21 10:23:14 AM ET
      $BCYP
      Finance
    • Ladenburg Thalmann initiated coverage on Big Cypress Acquisition with a new price target

      Ladenburg Thalmann initiated coverage of Big Cypress Acquisition with a rating of Buy and set a new price target of $16.50

      10/1/21 7:00:04 AM ET
      $BCYP
      Finance

    $BCYP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 7:38:40 PM ET
      $BCYP
      Finance
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 4:57:43 PM ET
      $BCYP
      Finance
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 4:55:01 PM ET
      $BCYP
      Finance